Scholarlink

Background <p>Disease reactivation following cessation of sphingosine 1-phosphate receptor modulators (S1PRM) occurs in ~ 10% of multiple sclerosis (MS) patients. The biological factors underlying this phenomenon remain incompletely understood, including the potential contribution of sex-specific differences.</p> Methods <p>We performed a systematic review on published literature and adverse event registries (FAERS, EudraVigilance), as of January 2024, focusing exclusively on fingolimod (FTY) withdrawal in individuals with MS. Disease severity after FTY withdrawal was assessed in the experimental autoimmune encephalomyelitis (EAE) mouse model, using untreated EAE mice as controls. S1P receptor expression was analyzed by immunofluorescence in spinal cord tissue from EAE mice and in brain biopsies from MS patients with disease reactivation after FTY withdrawal and MS controls (no prior FTY or S1PRM treatment).</p> Results <p>Analysis of eight studies (n = 2579) demonstrated an association between female sex and disease reactivation after FTY cessation (odds ratios: 1.09–7.20), corroborated by pharmacovigilance data (FAERS: OR = 2.00, <i>p</i> &lt; 0.0001; EudraVigilance: OR = 2.42, <i>p</i> &lt; 0.0001). Female EAE mice exhibited greater post-FTY treatment disease severity (2.5-fold increase, <i>p</i> &lt; 0.0001) with increased S1PR1 expression on CD3<sup>+</sup>T cells (<i>p</i> &lt; 0.001). Human brain biopsies showed elevated S1PR1 expression on CD3<sup>+</sup>T cells in active demyelinating lesions during disease reactivation compared to inactive demyelinated lesions (<i>p</i> &lt; 0.0001) and controls (<i>p</i> &lt; 0.05).</p> Discussion <p>Across clinical, experimental, and neuropathological analyses, female sex was associated with more pronounced disease activity following FTY withdrawal. Increased S1PR1 expression in T cells represents a potential cellular correlate of this sex-associated vulnerability and warrants further mechanistic investigation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Higher disease reactivation risk in women after fingolimod withdrawal

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月17日

查看全文
  • Marine Massy,
  • Stefanie Marti,
  • Adriane Kutllovci,
  • Niklas Frahm,
  • Firas Fneish,
  • David Ellenberger,
  • Helly Hammer,
  • Andrew Chan,
  • Alexander Leichtle,
  • Fred Lühder,
  • Imke Metz,
  • Maximilian Pistor,
  • Robert Hoepner

摘要

Background

Disease reactivation following cessation of sphingosine 1-phosphate receptor modulators (S1PRM) occurs in ~ 10% of multiple sclerosis (MS) patients. The biological factors underlying this phenomenon remain incompletely understood, including the potential contribution of sex-specific differences.

Methods

We performed a systematic review on published literature and adverse event registries (FAERS, EudraVigilance), as of January 2024, focusing exclusively on fingolimod (FTY) withdrawal in individuals with MS. Disease severity after FTY withdrawal was assessed in the experimental autoimmune encephalomyelitis (EAE) mouse model, using untreated EAE mice as controls. S1P receptor expression was analyzed by immunofluorescence in spinal cord tissue from EAE mice and in brain biopsies from MS patients with disease reactivation after FTY withdrawal and MS controls (no prior FTY or S1PRM treatment).

Results

Analysis of eight studies (n = 2579) demonstrated an association between female sex and disease reactivation after FTY cessation (odds ratios: 1.09–7.20), corroborated by pharmacovigilance data (FAERS: OR = 2.00, p < 0.0001; EudraVigilance: OR = 2.42, p < 0.0001). Female EAE mice exhibited greater post-FTY treatment disease severity (2.5-fold increase, p < 0.0001) with increased S1PR1 expression on CD3+T cells (p < 0.001). Human brain biopsies showed elevated S1PR1 expression on CD3+T cells in active demyelinating lesions during disease reactivation compared to inactive demyelinated lesions (p < 0.0001) and controls (p < 0.05).

Discussion

Across clinical, experimental, and neuropathological analyses, female sex was associated with more pronounced disease activity following FTY withdrawal. Increased S1PR1 expression in T cells represents a potential cellular correlate of this sex-associated vulnerability and warrants further mechanistic investigation.